A novel LC-MS/MS-based assay for the simultaneous quantification of aldosterone-related steroids in human urine
Author:
Vogg Nora12ORCID, Kürzinger Lydia1, Kendl Sabine12, Pamporaki Christina3, Eisenhofer Graeme3ORCID, Adolf Christian4, Hahner Stefanie1, Fassnacht Martin12, Kurlbaum Max12ORCID
Affiliation:
1. Department of Internal Medicine I, Division of Endocrinology and Diabetes, University Hospital , University of Würzburg , Würzburg , Germany 2. Central Laboratory, Core Unit Clinical Mass Spectrometry , University Hospital Würzburg , Würzburg , Germany 3. Department of Internal Medicine III, University Hospital Carl Gustav Carus , Technische Universität Dresden , Dresden , Germany 4. Medizinische Klinik und Poliklinik IV, Klinikum der Universität München , LMU München , Munich , Germany
Abstract
Abstract
Objectives
Primary aldosteronism is the most common cause of endocrine hypertension and is associated with significant cardiovascular morbidities. The diagnostic workup depends on determinations of plasma aldosterone and renin which are highly variable and associated with false-positive and false-negative results. Quantification of aldosterone in 24 h urine may provide more reliable results, but the methodology is not well established. We aimed to establish an assay for urinary aldosterone and related steroids with suitability for clinical routine implementation.
Methods
Here, we report on the development and validation of a quantitative LC-MS/MS method for six urinary steroids: aldosterone, cortisol, 18-hydroxycorticosterone, 18-hydroxycortisol, 18-oxocortisol, tetrahydroaldosterone. After enzymatic deconjugation, total steroids were extracted using SepPak tC18 plates and quantified in positive electrospray ionization mode on a QTRAP 6500+ mass spectrometer.
Results
Excellent linearity was demonstrated with R2>0.998 for all analytes. Extraction recoveries were 89.8–98.4 % and intra- and inter-day coefficients of variations were <6.4 and <9.0 %, establishing superb precision. Patients with primary aldosteronism (n=10) had higher mean 24 h excretions of aldosterone-related metabolites than normotensive volunteers (n=20): 3.91 (95 % CI 2.27–5.55) vs. 1.92 (1.16–2.68) µmol/mol for aldosterone/creatinine, 2.57 (1.49–3.66) vs. 0.79 (0.48–1.10) µmol/mol for 18-hydroxycorticosterone/creatinine, 37.4 (13.59–61.2) vs. 11.61 (10.24–12.98) µmol/mol for 18-hydroxycortisol/creatinine, 1.56 (0.34–2.78) vs. 0.13 (0.09–0.17) µmol/mol for 18-oxocortisol/creatinine, and 21.5 (13.4–29.6) vs. 7.21 (4.88–9.54) µmol/mol for tetrahydroaldosterone/creatinine.
Conclusions
The reported assay is robust and suitable for routine clinical use. First results in patient samples, though promising, require clinical validation in a larger sample set.
Funder
Bayerische Forschungsstiftung Deutsche Forschungsgemeinschaft
Publisher
Walter de Gruyter GmbH
Subject
Biochemistry (medical),Clinical Biochemistry,General Medicine
Reference40 articles.
1. Milliez, P, Girerd, X, Plouin, PF, Blacher, J, Safar, ME, Mourad, JJ. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol 2005;45:1243–8. https://doi.org/10.1016/j.jacc.2005.01.015. 2. Monticone, S, D’Ascenzo, F, Moretti, C, Williams, TA, Veglio, F, Gaita, F, et al.. Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: a systematic review and meta-analysis. Lancet Diabetes Endocrinol 2018;6:41–50. https://doi.org/10.1016/s2213-8587(17)30319-4. 3. Reincke, M, Bancos, I, Mulatero, P, Scholl, UI, Stowasser, M, Williams, TA. Diagnosis and treatment of primary aldosteronism. Lancet Diabetes Endocrinol 2021;9:876–92. https://doi.org/10.1016/s2213-8587(21)00210-2. 4. Kayser, SC, Dekkers, T, Groenewoud, HJ, van der Wilt, GJ, Carel Bakx, J, van der Wel, MC, et al.. Study heterogeneity and estimation of prevalence of primary aldosteronism: a systematic review and meta-regression analysis. J Clin Endocrinol Metab 2016;101:2826–35. https://doi.org/10.1210/jc.2016-1472. 5. Vaidya, A, Hundemer, GL, Nanba, K, Parksook, WW, Brown, JM. Primary aldosteronism: state-of-the-art review. Am J Hypertens 2022;35:967–88. https://doi.org/10.1093/ajh/hpac079.
|
|